Related Experiment Video

Updated: Aug 8, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma

Manzar Alam1, Gulam Mustafa Hasan2, Sayed M Eldin3

  • 1Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|March 6, 2023
PubMed

Insights

This review details how genetic changes in signaling molecules drive non-small cell lung carcinoma (NSCLC) and discusses targeted therapies. Understanding these pathways is key to developing effective NSCLC treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Non-small cell lung carcinoma (NSCLC) is a prevalent global malignancy.
  • Genetic alterations in signaling molecules disrupt normal cellular pathways, leading to cancer.
  • Dysregulated signaling contributes to tumor growth, proliferation, and resistance to therapies.

Purpose of the Study:

  • To provide a comprehensive review of the molecular mechanisms underlying NSCLC.
  • To elucidate the role of signaling cascades in cancer development and drug resistance.
  • To highlight the therapeutic potential of targeting specific signaling pathways in NSCLC.

Main Methods:

  • Literature review of current research on NSCLC signaling pathways.
  • Analysis of molecular mechanisms involving transcription factors and related pathways.
  • Examination of targeted therapeutic strategies for NSCLC management.

Main Results:

  • Signaling pathway dysregulation is a critical driver of NSCLC.
  • Targeting specific molecular pathways offers promising therapeutic avenues.
  • Understanding molecular mechanisms informs the development of novel NSCLC treatments.

Conclusions:

  • Targeted inhibitors of cellular signaling pathways represent a key strategy for NSCLC treatment.
  • Further research into molecular mechanisms will advance clinical management of NSCLC.
  • This review offers insights into the molecular basis of NSCLC and its therapeutic targeting.
Keywords:
ApoptosisCancer signalingNon-small cell lung carcinomaSmall molecule inhibitorsTargeted therapy, Drug development

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.3K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
7.3K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.6K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
8.8K